FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095462014> ?p ?o ?g. }

• W3095462014 endingPage "17" @default.
• W3095462014 startingPage "15" @default.
• W3095462014 abstract "Introduction: The activity of immune checkpoint blockade including anti-cytotoxic T-lymphocyte associated protein-4 and anti-programmed cell death protein-1 monoclonal antibodies in hematologic malignancies is limited outside of classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Tumor mutational burden (TMB), programmed death ligand-1 (PD-L1) expression, and microsatellite instability-high (MSI-H) are well-established biomarkers predicting response to checkpoint blockade in solid malignancies. In addition, tumors with high TMB, defined as ≥10 mutations/megabase (mut/Mb), and/or MSI-H are Food and Drug Administration (FDA) approved tissue agnostic biomarkers for treatment with pembrolizumab. The frequencies of high TMB, MSI-H, and expression pattern of PD-L1 across specific hematologic malignancies are undefined. Methods: Patients with hematologic malignancies who had next generation sequencing (NGS) performed by Foundation One Heme were identified. TMB and MSI were measured by NGS. TMB was classified as high if ≥10 mut/Mb and low if &lt;10 mut/Mb. When available, PD-L1 expression on tumor cells by immunohistochemistry (IHC) was also collected. PD-L1 IHC was performed with either Ventana (SP142) PD-L1 antibody or Dako (22C3) PD-L1 antibody. Scores were classified as high (≥ 50%), low (1-49%), and negative (&lt;1%) based on the percent of tumor cells staining positive for PD-L1. Pathology reports were retrospectively re-reviewed to determine the diagnosis. Results: A total of 390 patients with hematologic malignancies with NGS were identified. Forty eight of the 390 samples (12%) had a high TMB (Table 1). Twenty five of 45 (56%) patients with DLBCL had a high TMB (Table 2). The TMB was low in all myeloid malignancies tested. None of the 302 samples tested were MSI-H. PD-L1 IHC was performed on 86 samples. Eleven (13%) had high expression, 26 (30%) had low expression, and 49 (57%) had no expression of PD-L1 on the tumor cells (Table 1). The majority of samples with PD-L1 expression were mature lymphomas (81%). TMB and PD-L1 score had a significant linear relationship (R = 0.22,p= 0.04, 95% CI 0.01 - 0.41) (Figure 1). Conclusion: This study provides detailed characteristics of TMB, MSI status, and PD-L1 expression for hematologic malignancies. Notably, a subset of lymphomas had high TMB and/or PD-L1 expression. Biomarker driven studies of checkpoint blockade in hematologic malignancies with high TMB and/or PD-L1 expression are warranted. Disclosures Sokol: Foundation Medicine:Current Employment;Roche:Current equity holder in publicly-traded company.Kurzrock:Medimmune:Research Funding;Foundation Medicine:Research Funding;Konica Minolta:Research Funding;IDbyDNA:Current equity holder in private company;Pfizer:Consultancy, Research Funding;Sequenom:Research Funding;Bicara Therapeutics, Inc.:Consultancy;Incyte:Research Funding;Takeda:Research Funding;TopAlliance:Research Funding;Boehringer Ingelheim:Research Funding;CureMatch Inc:Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees;Grifols:Research Funding;Guardant:Research Funding;X Biotech:Consultancy;Neomed:Consultancy;Actuate Therapeutics:Consultancy;Roche:Consultancy;Merck Serono:Research Funding;Genentech:Research Funding;Debiopharm:Research Funding;CureMetrix:Membership on an entity's Board of Directors or advisory committees;OmniSeq:Research Funding;TD2/Volastra:Consultancy;Turning Point Therapeutics:Consultancy.Goodman:EUSA Pharma:Consultancy;Seattle Genetics:Consultancy." @default.
• W3095462014 created "2020-11-09" @default.
• W3095462014 creator A5022835631 @default.
• W3095462014 creator A5052965408 @default.
• W3095462014 creator A5053481267 @default.
• W3095462014 creator A5057166827 @default.
• W3095462014 creator A5062512082 @default.
• W3095462014 creator A5075636598 @default.
• W3095462014 date "2020-11-05" @default.
• W3095462014 modified "2023-10-16" @default.
• W3095462014 title "Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies" @default.
• W3095462014 doi "https://doi.org/10.1182/blood-2020-134375" @default.
• W3095462014 hasPublicationYear "2020" @default.
• W3095462014 type Work @default.
• W3095462014 sameAs 3095462014 @default.
• W3095462014 citedByCount "0" @default.
• W3095462014 crossrefType "journal-article" @default.
• W3095462014 hasAuthorship W3095462014A5022835631 @default.
• W3095462014 hasAuthorship W3095462014A5052965408 @default.
• W3095462014 hasAuthorship W3095462014A5053481267 @default.
• W3095462014 hasAuthorship W3095462014A5057166827 @default.
• W3095462014 hasAuthorship W3095462014A5062512082 @default.
• W3095462014 hasAuthorship W3095462014A5075636598 @default.
• W3095462014 hasBestOaLocation W30954620141 @default.
• W3095462014 hasConcept C104317684 @default.
• W3095462014 hasConcept C121608353 @default.
• W3095462014 hasConcept C126322002 @default.
• W3095462014 hasConcept C142724271 @default.
• W3095462014 hasConcept C159654299 @default.
• W3095462014 hasConcept C180754005 @default.
• W3095462014 hasConcept C203014093 @default.
• W3095462014 hasConcept C204232928 @default.
• W3095462014 hasConcept C2777701055 @default.
• W3095462014 hasConcept C2779338263 @default.
• W3095462014 hasConcept C2779767149 @default.
• W3095462014 hasConcept C2780057760 @default.
• W3095462014 hasConcept C2780851360 @default.
• W3095462014 hasConcept C2781053074 @default.
• W3095462014 hasConcept C502942594 @default.
• W3095462014 hasConcept C55493867 @default.
• W3095462014 hasConcept C61320498 @default.
• W3095462014 hasConcept C71924100 @default.
• W3095462014 hasConcept C86803240 @default.
• W3095462014 hasConceptScore W3095462014C104317684 @default.
• W3095462014 hasConceptScore W3095462014C121608353 @default.
• W3095462014 hasConceptScore W3095462014C126322002 @default.
• W3095462014 hasConceptScore W3095462014C142724271 @default.
• W3095462014 hasConceptScore W3095462014C159654299 @default.
• W3095462014 hasConceptScore W3095462014C180754005 @default.
• W3095462014 hasConceptScore W3095462014C203014093 @default.
• W3095462014 hasConceptScore W3095462014C204232928 @default.
• W3095462014 hasConceptScore W3095462014C2777701055 @default.
• W3095462014 hasConceptScore W3095462014C2779338263 @default.
• W3095462014 hasConceptScore W3095462014C2779767149 @default.
• W3095462014 hasConceptScore W3095462014C2780057760 @default.
• W3095462014 hasConceptScore W3095462014C2780851360 @default.
• W3095462014 hasConceptScore W3095462014C2781053074 @default.
• W3095462014 hasConceptScore W3095462014C502942594 @default.
• W3095462014 hasConceptScore W3095462014C55493867 @default.
• W3095462014 hasConceptScore W3095462014C61320498 @default.
• W3095462014 hasConceptScore W3095462014C71924100 @default.
• W3095462014 hasConceptScore W3095462014C86803240 @default.
• W3095462014 hasIssue "Supplement 1" @default.
• W3095462014 hasLocation W30954620141 @default.
• W3095462014 hasOpenAccess W3095462014 @default.
• W3095462014 hasPrimaryLocation W30954620141 @default.
• W3095462014 hasRelatedWork W2346089412 @default.
• W3095462014 hasRelatedWork W2437736820 @default.
• W3095462014 hasRelatedWork W2845852940 @default.
• W3095462014 hasRelatedWork W2920863623 @default.
• W3095462014 hasRelatedWork W2970048128 @default.
• W3095462014 hasRelatedWork W3001177628 @default.
• W3095462014 hasRelatedWork W4206362823 @default.
• W3095462014 hasRelatedWork W4220781313 @default.
• W3095462014 hasRelatedWork W4292838584 @default.
• W3095462014 hasRelatedWork W4294343845 @default.
• W3095462014 hasVolume "136" @default.
• W3095462014 isParatext "false" @default.
• W3095462014 isRetracted "false" @default.
• W3095462014 magId "3095462014" @default.
• W3095462014 workType "article" @default.